Skip to main content

Dr. Harry Menon, DO, MPH

Hematology & Oncology (Hematology & Oncology Physician)

1155 Mill St
Reno, NV 89502

Who else practices at this address →

Washoe County includes primary care (2% of residents) shortage areas. About shortage areas

Call (775) 982-5436

  • Medicare participating

At a glance

Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
297

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: Lake Erie Col of Osteopathic Medicine, Bradenton
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    NV license DO2896
  • Internal Medicine Physician
    NV license DO2896
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
297
Services billed
876
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes363118
Established patient office or other outpatient visit, 20-29 minutes9868
New patient office or other outpatient visit, 60-74 minutes5454
Established patient office or other outpatient visit, 40-54 minutes2423

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 32 companies reported 94 payments worth $48,855 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$21,969
Consulting Fee$21,529
Food and Beverage$3,166
Travel and Lodging$2,190

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 29, 2025Genzyme Corporation
Jan 29, 2025
Compensation for services other than consulting (speaking, faculty)
SARCLISA · Oncology
$9,309
Aug 20, 2025Genentech USA, Inc.
Aug 20, 2025
Consulting Fee
Lunsumio; Columvi; Polivy · BioOncology
$5,539
Nov 1, 2025Genzyme Corporation
Nov 1, 2025
Consulting Fee$5,430
Jun 27, 2025AstraZeneca Pharmaceuticals LP
Jun 27, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$5,360
May 16, 2025AstraZeneca Pharmaceuticals LP
May 16, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$5,360
Aug 21, 2025Genentech USA, Inc.
Aug 21, 2025
Consulting Fee
Lunsumio; Columvi; Polivy · BioOncology
$4,209
Nov 12, 2025Pfizer Inc.
Nov 12, 2025
Consulting Fee
ELREXFIO · ONCOLOGY
$2,100
Jun 25, 2025Incyte Corporation
Jun 25, 2025
Consulting Fee$1,925
May 12, 2025AstraZeneca Pharmaceuticals LP
May 12, 2025
Consulting Fee
IMFINZI · Oncology
$1,675
Aug 19, 2025AstraZeneca Pharmaceuticals LP
Aug 19, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$1,340
All 19 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 5, 2025AstraZeneca Pharmaceuticals LP
Dec 5, 2025
Compensation for services other than consulting (speaking, faculty)
IMFINZI · Oncology
Company’s descriptionSpeaker Fee
$300
Dec 5, 2025AstraZeneca Pharmaceuticals LP
Dec 5, 2025
Compensation for services other than consulting (speaking, faculty)
IMFINZI · Oncology
Company’s descriptionSpeaker Fee
$300
Nov 12, 2025Pfizer Inc.
Nov 12, 2025
Consulting Fee
ELREXFIO · ONCOLOGY
$2,100
Nov 1, 2025Genzyme Corporation
Nov 1, 2025
Consulting Fee$5,430
Sep 22, 2025Daiichi Sankyo Inc.
Sep 22, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$650
Aug 21, 2025Genentech USA, Inc.
Aug 21, 2025
Consulting Fee
Lunsumio; Columvi; Polivy · BioOncology
$4,209
Aug 20, 2025Genentech USA, Inc.
Aug 20, 2025
Consulting Fee
Lunsumio; Columvi; Polivy · BioOncology
$5,539
Aug 20, 2025Genentech USA, Inc.
Aug 20, 2025
Travel and Lodging
Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind
$474
Aug 20, 2025Genentech USA, Inc.
Aug 20, 2025
Travel and Lodging
Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind
$390
Aug 20, 2025Genentech USA, Inc.
Aug 20, 2025
Travel and Lodging
Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind
$34.61
Aug 19, 2025AstraZeneca Pharmaceuticals LP
Aug 19, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$1,340
Jul 2, 2025AstraZeneca Pharmaceuticals LP
Jul 2, 2025
Travel and Lodging
travel to Granite Bay, CA
$178
Jun 27, 2025AstraZeneca Pharmaceuticals LP
Jun 27, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$5,360
Jun 25, 2025Incyte Corporation
Jun 25, 2025
Consulting Fee$1,925
May 16, 2025AstraZeneca Pharmaceuticals LP
May 16, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$5,360
May 14, 2025AstraZeneca Pharmaceuticals LP
May 14, 2025
Travel and Lodging
travel to Anchorage, AK · in-kind
Company’s descriptionSpeaker Expenses
$1,043
May 12, 2025AstraZeneca Pharmaceuticals LP
May 12, 2025
Consulting Fee
IMFINZI · Oncology
$1,675
Jan 29, 2025Genzyme Corporation
Jan 29, 2025
Compensation for services other than consulting (speaking, faculty)
SARCLISA · Oncology
$9,309
Jan 29, 2025Genzyme Corporation
Jan 29, 2025
Travel and Lodging
SARCLISA · Oncology · travel to Las Vegas, NV
$70.74

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Nevada →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $110,893 in research payments for these studies, mostly to the institutions running them.

  • An interventional openlabel phase 1B2 study to evaluate safety pharmacokinetics and preliminary efficacy of PF08634404 as monotherapy and combination therapy in adult participants with unresectable locally advanced or…
    Pfizer Inc.
  • A phase 2B3 randomized doubleblind study to investigate the efficacy safety and tolerability of ponsegromab PF06946860 compared with placebo both with background firstline chemotherapy in adult participants with cache…
    Pfizer Inc.
  • A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
    AstraZeneca Pharmaceuticals LP
  • A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated…
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Reno

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 13, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1265826390. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.